Q-omics provides the consensus-scored CCDC144A profile across patient tissues and cancer cell-line models. CCDC144A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC144A is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, CCDC144A RNA expression shows 16,047 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, UCEC, and THYM as cancer lineages where CCDC144A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC144A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC144A survival associations across molecular data types. CCDC144A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC144A RNA expression–survival associations across cancer types. High CCDC144A expression shows unfavorable associations in UVM, CHOL, CESC, MESO and ACC, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC144A RNA expression.
This table summarizes CCDC144A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC144A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC144A shows lower tumor expression in UCEC, COAD and LUSC and higher tumor expression in KICH and KIRC. The UCEC box plot shows higher CCDC144A RNA expression in normal versus tumor tissue (log2 FC = −0.170, t-test p = .008).
This table shows molecular features associated with CCDC144A in patient tissues and cancer cell lines. In patient samples, CCDC144A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC144A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
